RxDoctor Payments Data

Gaurav Zirath, MD

Family Medicine · Redlands, CANPI 1205281292

Payments from drug & device makers

$6,505in general payments, 2019–2025

Across 21 payments — averaging $309.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
  • Novo Nordisk$153
  • Johnson & Johnson$93
  • AstraZeneca$72
  • Dexcom, Inc.$36
  • Merck$17
  • plus $32 from 2 others

What the payments were for

  • Consulting fees$4,69072%
  • Travel & lodging$1,22319%
  • Food & beverage$5939%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,505 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$15,213
Medicare patients
89
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide68$109,413
JardianceEmpagliflozin63$95,805
Soliqua 100-33Insulin Glargine/Lixisenatide14$26,992
EliquisApixaban22$22,817
MounjaroTirzepatide16$19,232
FarxigaDapagliflozin Propanediol14$17,552
LinzessLinaclotide22$16,067
OzempicSemaglutide13$14,240
Tresiba Flextouch U-100Insulin Degludec16$8,225
SymbicortBudesonide/Formoterol Fumarate21$6,607
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$4,225
Atorvastatin Calcium313$2,533
Albuterol Sulfate HfaAlbuterol Sulfate61$2,041
Omeprazole90$1,995
Gabapentin130$1,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$72$24,16035 claims
PfizerEliquis$16$22,81722 claims
Novo NordiskOzempic$153$14,24013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →